Given the task definition, example input & output, solve the new input case.
In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
Example: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Output: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

New input case for you: SECTION 1. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF PRESCRIPTION
OPIOIDS.

(a) Definitions.--In this section--
(1) the term ''Secretary'' means the Secretary of Health
and Human Services; and
(2) the term ''task force'' means the Pain Management Best
Practices Inter-Agency Task Force convened under subsection
(b).
(b) Inter-Agency Task Force.--Not later than December 14, 2018, the
Secretary, in cooperation with the Secretary of Veterans Affairs, the
Secretary of Defense, and the Administrator of the Drug Enforcement
Administration, shall convene a Pain Management Best Practices Inter-
Agency Task Force to review, modify, and update, as appropriate, best
practices for pain management (including chronic and acute pain) and
prescribing pain medication.
(c) Membership.--The task force shall be comprised of--
(1) representatives of--
(A) the Department of Health and Human Services;
(B) the Department of Veterans Affairs;
(C) the Food and Drug Administration;
(D) the Department of Defense;
(E) the Drug Enforcement Administration;
(F) the Centers for Disease Control and Prevention;
(G) the Health Resources and Services
Administration;
(H) the Indian Health Service;
(I) the National Academy of Medicine;
(J) the National Institutes of Health;
(K) the Office of National Drug Control Policy;
(L) the Substance Abuse and Mental Health Services
Administration; and
(M) the Office of Women's Health;
(2) State medical boards;
(3) subject to subsection (e), physicians, dentists, and
nonphysician prescribers;
(4) hospitals;
(5) subject to subsection (e), pharmacists and pharmacies;
(6) first responders;
(7) experts in the fields of pain research and addiction
research;
(8) experts in the fields of adolescent and young adult
addiction research;
(9) representatives of--
(A) pain management professional organizations;
(B) the mental health treatment community;
(C) the addiction treatment and recovery community;
(D) pain advocacy groups;
(E) veteran service organizations; and
(F) groups with expertise on overdose reversal;
(10) a person in recovery from addiction to medication for
chronic pain;
(11) a person in recovery from addiction to medication for
chronic pain, whose addiction began in adolescence or young
adulthood;
(12) a person with chronic pain;
(13) an expert on active duty military, armed forces
personnel, and veteran health and prescription opioid
addiction;
(14) an expert in the field of minority health; and
(15) other stakeholders, as the Secretary determines
appropriate.
(d) Condition on Participation on Task Force.--An individual
representing a profession or entity described in paragraph (3) or (5)
of subsection (c) may not serve as a member of the task force unless
such individual--
(1) is currently licensed in a State in which such
individual is practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, a State in which the entity is engaged in business);
and
(2) is currently practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, the entity is in operation).
(e) Duties.--The task force shall--
(1) not later than 180 days after the date on which the
task force is convened under subsection (b), review, modify,
and update, as appropriate, best practices for pain management
(including chronic and acute pain) and prescribing pain
medication, taking into consideration--
(A) existing pain management research;
(B) research on trends in areas and communities in
which the prescription opioid abuse rate and fatality
rate exceed the national average prescription opioid
abuse rate and fatality rate;
(C) recommendations from relevant conferences and
existing relevant evidence-based guidelines;
(D) ongoing efforts at the State and local levels
and by medical professional organizations to develop
improved pain management strategies, including
consideration of differences within and between classes
of opioids, the availability of opioids with abuse
deterrent technology, and pharmacological,
nonpharmacological, medical device alternatives to
opioids to reduce opioid monotherapy in appropriate
cases and the coordination of information collected
from State prescription drug monitoring programs for
the purpose of preventing the diversion of pain
medication;
(E) ongoing efforts at the Federal, State, and
local levels to examine the potential benefits of
electronic prescribing of opioids, including any public
comments collected in the course of those efforts;
(F) the management of high-risk populations, other
than populations who suffer pain, who--
(i) may use or be prescribed
benzodiazepines, alcohol, and diverted opioids;
or
(ii) receive opioids in the course of
medical care;
(G) the distinct needs of adolescents and young
adults with respect to pain management, pain
medication, substance use disorder, and medication-
assisted treatment;
(H) the 2016 Guideline for Prescribing Opioids for
Chronic Pain issued by the Centers for Disease Control
and Prevention;
(I) the practice of co-prescribing naloxone for
both pain patients receiving chronic opioid therapy and
patients being treated for opioid use disorders;
(J) research that has been, or is being, conducted
or supported by the Federal Government on prevention
of, treatment for, and recovery from substance use by
and substance use disorders among adolescents and young
adults relative to any unique circumstances (including
social and biological circumstances) of adolescents and
young adults that may make adolescent-specific and
young adult-specific treatment protocols necessary,
including any effects that substance use and substance
use disorders may have on brain development and the
implications for treatment and recovery;
(K) Federal non-research programs and activities
that address prevention of, treatment for, and recovery
from substance use by and substance use disorders among
adolescents and young adults, including an assessment
of the effectiveness of such programs and activities
in--
(i) preventing substance use by and
substance use disorders among adolescents and
young adults;
(ii) treating such adolescents and young
adults in a way that accounts for any unique
circumstances faced by adolescents and young
adults; and
(iii) supporting long-term recovery among
adolescents and young adults; and
(L) gaps that have been identified by Federal
officials and experts in Federal efforts relating to
prevention of, treatment for, and recovery from
substance use by and substance use disorders among
adolescents and young adults, including gaps in
research, data collection, and measures to evaluate the
effectiveness of Federal efforts, and the reasons for
such gaps;
(2) solicit and take into consideration public comment on
the practices developed under paragraph (1), amending such best
practices if appropriate;
(3) develop a strategy for disseminating information about
the best practices developed under paragraphs (1) and (2) to
prescribers, pharmacists, State medical boards, educational
institutions that educate prescribers and pharmacists, and
other parties, as the Secretary determines appropriate;
(4) review, modify, and update best practices for pain
management and prescribing pain medication, specifically as it
pertains to physician education and consumer education; and
(5) examine and identify--
(A) the extent of the need for the development of
new pharmacological, nonpharmacological, and medical
device alternatives to opioids;
(B) the current status of research efforts to
develop such alternatives; and
(C) the pharmacological, nonpharmacological, and
medical device alternatives to opioids that are
currently available that could be better utilized.
(f) Consideration of Study Results.--In reviewing, modifying, and
updating, best practices for pain management and prescribing pain
medication, the task force shall take into consideration existing
private sector, State, and local government efforts related to pain
management and prescribing pain medication.
(g) Limitation.--The task force shall not have rulemaking
authority.
(h) Report.--Not later than 270 days after the date on which the
task force is convened under subsection (b), the task force shall
submit to Congress a report that includes--
(1) the strategy for disseminating best practices for pain
management (including chronic and acute pain) and prescribing
pain medication, as developed under subsection (e);
(2) the results of a feasibility study on linking the best
practices described in paragraph (1) to receiving and renewing
registrations under section 303(f) of the Controlled Substances
Act (21 U.S.C. 823(f));
(3) recommendations for effectively applying the best
practices described in paragraph (1) to improve prescribing
practices at medical facilities, including medical facilities
of the Veterans Health Administration and Indian Health
Service;
(4) the modified and updated best practices described in
subsection (e)(4); and
(5) the results of the examination and identification
conducted pursuant to subsection (e)(4), and recommendations
regarding--
(A) the development of new pharmacological,
nonpharmacological, and medical device alternatives to
opioids; and
(B) the improved utilization of pharmacological,
nonpharmacological, and medical device alternatives to
opioids that are currently available.

Passed the House of Representatives May 11, 2016.

Attest:

KAREN L. HAAS,

Clerk.
Output:
(Sec. 1) This bill requires the Department of Health and Human Services to convene a Pain Management Best Practices Inter-Agency Task Force to: (1) review, modify, and update best practices for pain management and prescribing pain medication; and (2) examine and identify the need for, development of, and availability of medical alternatives to opioids (drugs with effects similar to opium, such as certain pain medications). The task force must submit a report that includes: (1) the modified and updated best practices; (2) a strategy for disseminating the best practices; (3) the feasibility of linking the best practices to Drug Enforcement Administration registration of manufacturers, distributors, and dispensers of controlled substances; (4) recommendations for effectively applying the best practices at medical facilities; and (5) recommendations regarding medical alternatives to opioids.